Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06717867

Long-Term PEA Safety Study

The goal of this clinical trial is to learn about the long term safety of PEA supplementation in healthy adults. This clinical trial will be in both males and females who are 18 years or older and are healthy volunteers.

The main aim of the study is to assess the safety of long-term use of PEA by assessing the difference between the two groups for serious adverse events, non-serious adverse events, vital signs and biochemistry following 12 months of PEA supplementation.

Participants will:

* Have their suitability for the study checked against the full inclusion/exclusion criteria during the screening process. * Eligible participants will then complete a baseline visit where assessments will be performed and the participant will be randomly assigned to receive the study product or a placebo. Participants will then consume their assigned study product every day for 12 months. Participants will not know what product they have been assigned during the study. * Following the baseline visit, there will be 4 visits over 12 months. On months where participants do not have a visit there will be a check in phone call. * During visits there will be safety assessments performed, blood sampling and questionnaires.

The trial will include two participation modes:

1. In-clinic participation (Brisbane): Participants will attend all visits in-person at the RDC Clinical facility. 2. Remote participation for participants outside of Brisbane: A subgroup of up to 120 participants will participate remotely with virtual visits and at-home assessments. Participants will attend their local pathology centre for blood sampling.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy Safety

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

RDC Clinical

Brisbane, Queensland, 4006, Australia

Location status: Recruiting

Location contact

Amanda Rao

PRINCIPAL_INVESTIGATOR

Dr Amanda Rao

CONTACT

[email protected]

+61 (0) 414 488 559

About this study

This is an interventional, phase II, randomised, double-blind, placebo-controlled, parallel dose safety study in healthy adults to assess long term population exposure to Palmitoylethanolamide (Levagen™).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (18 years and older)
  • Generally healthy
  • Able to provide informed consent
  • BMI 18.5 - 35.0 kg/m2
  • Agree to not participate in another clinical trial during enrolment period

Exclusion criteria

  • Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
  • Serious illness e.g., mood disorders (such as depression or bipolar disorder), anxiety, neurological disorders (such as MS), kidney disease, liver disease or heart conditions
  • Unstable illness (e.g., diabetes and thyroid gland dysfunction)
  • History of renal function impairment
  • Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy [(excluding low dose aspirin (under 300 mg/day)]
  • Regular consumption (>4 times a week) of PEA over the past 2 weeks
  • Substance Abuse (illicit and/or prescription) Drug (prescription or illegal substances) abuse
  • Chronic past (within 12-months) and/or current alcohol use (>14 alcoholic drinks week)
  • Pregnant or lactating women
  • Allergic, sensitive, or intolerant to any of the ingredients in active or placebo formula
  • Has a clinically significant abnormal finding on the medical assessment, medical history, or clinical laboratory results at screening.
  • Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.
  • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Treatment and study plan

Palmitoylethanolamide (PEA)

Dietary Supplement

Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.

Other names: Levagen™

Placebo

Other

Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.

Primary outcomes

  1. Change from baseline to the end of the study period in participants with SAEs

    Time frame: From Day O (Baseline) to 54 weeks

    Change from baseline to the end of the study period in:

    Number of participants with Serious Adverse Events (SAE) after first administration of study drug through to the last dose of study drug plus 2 weeks [time frame: after first administration of study drug through to the last dose of study drug (12 months) plus 2 weeks (week 54)]

Secondary outcomes

  1. Change from baseline to month 12 in AEs

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in all adverse events (AEs)

  2. Change from baseline to month 12 in medical assessment

    Time frame: Baseline (day 0) and Month 12

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by Medical assessment (by a doctor).

    The Medical Assessment is a medical review to elucidate symptoms of any occult medical conditions will be conducted for all participants and a medical assessment will then be performed. The assessment will include a review of vital signs and measurements, general appearance, brief cranial nerve assessment, cardiovascular, gastrointestinal and respiratory assessments. Other body systems will be examined (e.g. neurological, renal, musculoskeletal, ear, nose and throat or skin) as is deemed necessary by the trial doctor as guided by the medical review.

  3. Change from baseline to month 12 in Vital Signs (blood pressure)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by blood pressure (mmHg).

  4. Change from baseline to month 12 in Vital Signs (heart rate)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by heart rate (bpm).

  5. Change from baseline to month 12 in clinical laboratory determinations (Full Blood Count)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by Full Blood Count (FBC).

  6. Change from baseline to month 12 in clinical laboratory determinations (fasting glucose)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by fasting glucose.

  7. Change from baseline to month 12 in clinical laboratory determinations (insulin)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by insulin.

  8. Change from baseline to month 12 in clinical laboratory determinations (lipids).

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by lipids.

  9. Change from baseline to month 12 in clinical laboratory determinations (electrolytes)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by electrolytes.

  10. Change from baseline to month 12 in clinical laboratory determinations (kidney function tests)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by kidney function tests.

  11. Change from baseline to month 12 in clinical laboratory determinations (Liver function tests)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by liver function tests.

  12. Change from baseline to month 12 in sleep questionnaires.

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Leeds sleep evaluation questionnaire (LSEQ).

    Each domain of the LSEQ is scored using a visual analogue scale (VAS) where participants mark their response on a line ranging from 0 to 100.

    Higher scores indicate better sleep quality or easier sleep-related behaviors in the respective domain. Lower scores indicate poorer sleep quality or more difficulty in the respective domain.

  13. Change from baseline to month 12 in anxiety questionnaires

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Anxiety questionnaires (Beck Anxiety Inventory Scale). Scores from 0 to 63, a score of 0-21 indicates low anxiety whereas a score of 36 and above indicates potentially concerning levels of anxiety.

  14. Change from baseline to month 12 in Quality of life

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Quality of life (RAND 36-Item Short Form Survey Instrument, Rand SF-36).

  15. Change from baseline to month 12 in Musculoskeletal health questionnaire

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Musculoskeletal health questionnaire (MSK-HQ). MSK-HQ is scored on a range of 0-56, with a better score indicating better MSK-HQ health status.

  16. Change from baseline to month 12 in Gastrointestinal tolerance questionnaire

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Gastrointestinal tolerance questionnaire

Other outcomes

  1. Exploratory: Change from baseline to month 12 in Vital Signs (temperature)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by temperature (celcius).

  2. Exploratory: Change from baseline to month 12 in Vital Signs (O2 saturation)

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in safety monitored by O2 saturation (%).

  3. Exploratory: Change from baseline to month 12 in PEA

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0, Visit 1) to the end of the study period (month 12, Visit 6) in PEA plasma concentration over time

  4. Exploratory: Change from baseline to month 12 in serum BDNF, CRP, and cytokines

    Time frame: Baseline (Day 0) to month 12.

    Change from baseline (Day 0) to the end of the study period (month 12) in safety monitored by Serum BDNF, CRP, and cytokines (e.g., IL-1b, IL-6, IL-10, TNF-a)]

Study contacts

Contact information is provided by the study sponsor or research team.

RV Venkatesh

CONTACT

[email protected]

(852) 2987 6894

Sponsors and collaborators

Lead sponsor

RDC Clinical Pty Ltd

Industry

Collaborators

  • Gencor Pacific Limited, Hong Kong

Registry information

Official study title

A Randomised, Double-blind Placebo-controlled Study in Healthy Adults to Assess Long Term Population Exposure to Palmitoylethanolamide (Levagen™) to Assess Clinical Safety.

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 5, 2024
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.